 Shares of Odonate Therapeutics Inc. plummeted 79.0 in active afternoon trading Monday, after the pharmaceutical company said it will wind down operations following disappointing data from its cancer treatment. The company said it determined, following feedback from the Food and Drug Administration in a pre-New Drug Application pre-NDA meeting, that tesetaxel, an orally administered chemotherapy agent, is unlikely to receive FDA approval. 